ASM beneficiary incentives involving technology are subject to the following additional conditions: (1) Items or services involving technology provided to an ASM beneficiary must be the minimum necessary to advance a clinical goal, as listed in paragraph (d) of this section, for an ASM beneficiary
3 Extended Administration Pharmacokinetics in DIO Mice Neelakantan et al., Biochemical Pharmacology (2024) This study reported a 28-day once-daily administration protocol of 5-Amino-1MQ in diet-induced obese mice, characterizing plasma pharmacokinetics, tissue distribution, and effects on body composition, fatty liver pathology, and circulating biomarkers
Am very pleased I used this and cut out sweets already (some ice cream)
We offer ongoing monitoring and support to track progress, address any side effects, and adjust care as neededensuring every family member receives optimal treatment
The discipline of waiting for trials, rather than substituting rodent data and case-series enthusiasm for them, is responsible and credible clinical judgement